IPO filing research

NODTHERA INC.

Pharmaceutical Preparations

ipo amended Nasdaq S-1

NODTHERA INC. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-10-21. Current deal snapshot: exchange Nasdaq.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange Nasdaq · Ticker RZRA

NodThera Inc. (now Rezera Inc.) is conducting an IPO with shares offered in the UK under specific conditions, including to qualified investors or with prior consent. The filing includes audited financial statements through 2025, highlighting significant losses, negative cash flows, and a going concern uncertainty. Legal counsel includes Goodwin Procter LLP and Gibson, Dunn & Crutcher LLP, with Deloitte & Touche LLP as auditors.

2026-10-21 · 0001104659-26-117853

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

NodThera Inc.'s current filing provides detailed disclosures about its financial statements, including accounting policies for convertible preferred stock, net loss per share calculations, and recent accounting standard adoptions. The document highlights the company's net loss position, accounting for R&D tax incentives in the UK, and tax considerations. It also outlines the impact of new accounting standards like ASU 2023-09 and ASU 2025-10 on financial disclosures.

2026-09-22 · 0001104659-26-109665

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

NodThera Inc. disclosed detailed financial reporting policies in its DRS/A filing, emphasizing net loss per share calculations using the two-class method for convertible preferred stock. The filing highlights significant accounting changes, including the adoption of ASU 2023-09 (income tax disclosures), ASU 2023-07 (segment reporting), and ASU 2025-10 (government grants). The company reported net losses of $42.2M (2025) and $25.2M (2024), with diluted net loss per share at $16.33 and $10.43 respectively. The filing also details U.K. R&D incentive credits and tax accounting policies.

2026-08-21 · 0001104659-26-099672

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

NodThera Inc.'s filing details accounting policies related to net loss per share calculations, convertible preferred stock classification, and recent accounting standard adoptions. The company reports net losses for 2025 and 2024, with specific disclosures about diluted share calculations, dividend preferences, and tax implications. Recent accounting changes include improved tax disclosures (ASU 2023-09), segment reporting enhancements (ASU 2023-07), and government grant accounting (ASU 2025-10). The filing also addresses foreign currency translation, R&D incentives, and potential tax uncertainties.

2026-07-07 · 0001104659-26-081296